Evidence map›Paper›PMID 40143959›Full record

ArticleJPRAS open2025

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 15-year Regional Burn Center Experience.

Dima Obed, Mustafa Salim, Khaled Dastagir, Nicco Krezdorn, Doha Obed, Peter M Vogt

Abstract read
In one paragraph

Article in JPRAS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dima ObedDepartment of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Hannover, Germany.
Mustafa SalimDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Khaled DastagirDepartment of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Hannover, Germany.
Nicco KrezdornDepartment of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Hannover, Germany.
Doha ObedDepartment of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Hannover, Germany.
Peter M VogtDepartment of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) constitute rare and potentially life-threatening dermal hypersensitivity reactions marked by epidermal necrosis and skin blistering. They present a substantial health care burden and challenge to burn units. To advance our understanding of TEN/SJS and the patient cohort at risk for mortality, we hereby report our long-term experience in the management of patients with TEN/SJS. For this purpose, intensive care patients with TEN/SJS admitted between 2007 and 2022 to a single major burn unit in Germany were assessed. Clinical, demographic, and mortality data were collected and examined. A total of 92 patients were included. Mortality was 46.7%, with non-survivors being significantly older, more frequently women, and having markedly higher percentages of the total body surface area (TBSA) affected. The mean age was 63 years and mean percentage of affected TBSA was 52%. The most frequent culprit drugs that caused TEN/SJS were allopurinol and metamizole, followed by various antibiotics. In 5.4% of the cases, no TEN/SJS-inducing suspect drug was identified. TEN/SJS present severe adverse cutaneous reactions that are marked by high in-hospital mortality rates. Age and TBSA were associated with poor prognosis. The range of possible trigger drugs that were associated with TEN/SJS was in agreement with previous reports.

Indexed as

Burn centerDrug reactionMortalityStevens–Johnson syndromeToxic epidermal necrolysis

Identifiers

PMID40143959
PMCPMC11938068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.